- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...

The AI2Health cluster of the Ken Kennedy Institute and the Synthetic Biology Institute at Rice University hosted a debriefing and collaborative discussion session on the Spirit of Asilomar summit June ...

Despite the hundreds of millions of vials of blood drawn every year for medical testing, scientists have only scratched the surface of its diagnostic potential. The blood proteome — which includes all ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical savvy and wide-ranging interest in the technological arts and sciences, Ars is ...